AC
XBIO icon

Armistice Capital’s Xenetic Biosciences XBIO Stock Holding History

Armistice Capital’s Portfolio XBIO Stock Details XBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-57,800
Closed -$1.19M – 180
2021
Q3 		$1.19M Buy
+57,800
New +$1.58M 0.02% 122

Other funds holding XBIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Armistice Capital's XBIO Position: Q4 2021 in Review

Armistice Capital sold out of Xenetic Biosciences (XBIO) in Q4 2021, closing a stake of 57,800 shares — an estimated $1.19M sold.

Armistice Capital first reported a position in XBIO in Q3 2021 and held it in 1 quarter. The position peaked at $1.19M in Q3 2021. 22 funds tracked by Wall St. Rank hold XBIO as of Q4 2021.

  • Armistice Capital reported no remaining Xenetic Biosciences position as of Q4 2021 after selling out during the quarter.
  • Armistice Capital sold 57,800 Xenetic Biosciences shares in Q4 2021, an estimated $1.19M.
  • Armistice Capital first reported a position in Xenetic Biosciences in Q3 2021 and held it in 1 quarter.
  • Armistice Capital's Xenetic Biosciences position peaked at $1.19M in Q3 2021.
  • 22 funds tracked by Wall St. Rank held Xenetic Biosciences as of Q4 2021.

Based on Armistice Capital's 13F filing for Q4 2021, filed 14 Feb 2022.